Yuichi Tominaga

Director
​Daiichi Sankyo Co., Ltd.

Yuichi Tominaga, PhD, is a director for Research Strategy & Planning Group in R&D Division, Daiichi Sankyo Co., Ltd. He is working as a leader of the open innovation initiative to help our scientists discover new lines of research through open innovation. After joining Daiichi Pharmaceutical in 1991, he has been working for many years in drug discovery field. He had a chance to receive education in University of California at San Francisco, Helen Diller Family Comprehensive Cancer Center in 2003 under the mentorship of Dr. Frank McCormick. After the merger of Daiichi Pharmaceutical and Sankyo, he was appointed as a senior director for Oncology Research Laboratories in 2012. After his carrier as a senior director in oncology small molecule drug discovery, he was on loan to Plexxikon as a visiting research fellow in 2015. He started working for the alliance management and open innovation in oncology area in 2017. He is a graduate of Kyoto University, and earned his PhD in pharmaceutical science from Kyoto University. 

Speech title & Synopsis

Open Innovation Strategy at Daiichi Sankyo

Daiichi Sankyo collaborates globally through variety of programs and is open to new collaborative research proposals at any time. Our goal is to jointly create new value for patients by maximizing each other’s expertise and strengths. We look for collaborative partners by use of partnering meetings like Bio International, Bio Asia-Taiwan, Bio Europe, and JP Morgan. You can see recent major reserch collaborations between Daiichi Sankyo and startups or academia on our Web site. We have formed comprehensive partnerships with the Max Planck Institute in Germany, Sanford Burnham in the US, the National Cancer Center Research Institute in Japan, the National Institute of Advanced Industrial Science and Technology in Japan to promote our research. 

We are seeking collaborative partners in academia and startups with disruptive science that have the potential to lead to transformative innovation. Daiichi Sankyo is eager to utilize its competitive new modalities and technologies to create novel technology platforms. We combine Daiichi Sankyo's modalities and technologies with external innovation in academia and startups leading to the creation of a competitive research pipeline based on disruptive science.